Enzymatica
3
SEK
-2.6 %
Less than 1K followers
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-2.6%
+77.51%
+89.87%
+72.41%
+15.38%
+0.76%
-50.83%
-36.61%
-47.49%
Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.
Read moreMarket cap
728.21M SEK
Turnover
245.27K SEK
Revenue
45.58M
EBIT %
-114.22 %
P/E
-
Dividend yield-%
-
Financial calendar
29.4
2025
Interim report Q1'25
7.5
2025
General meeting '25
17.7
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
Enzymatica AB: Replay Link to Digital Press Briefing - March 5, 2025
Enzymatica AB: Invitation to Press Briefing - 5 March 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools